Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Y-mAbs Therapeutics stock | $49.51

Own Y-mAbs Therapeutics stock in just a few minutes.

Fact checked

Y-mAbs Therapeutics, Inc is a biotechnology business based in the US. Y-mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Y-mAbs Therapeutics employs 65 staff and has a market cap (total outstanding shares value) of USD$2 billion.

How to buy shares in Y-mAbs Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Y-mAbs Therapeutics. Find the stock by name or ticker symbol: YMAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Y-mAbs Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$49.51, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Y-mAbs Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Y-mAbs Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Y-mAbs Therapeutics share price

Use our graph to track the performance of YMAB stocks over time.

Y-mAbs Therapeutics shares at a glance

Information last updated 2020-12-30.
Latest market closeUSD$49.51
52-week rangeUSD$14.16 - USD$55.22
50-day moving average USD$49.7162
200-day moving average USD$43.2619
Wall St. target priceUSD$59
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.83

Buy Y-mAbs Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Y-mAbs Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Y-mAbs Therapeutics price performance over time

Historical closes compared with the close of $49.51 from 2020-12-31

1 week (2021-01-06) N/A
1 month (2020-12-13) N/A
3 months (2020-10-13) N/A
6 months (2020-07-13) N/A
1 year (2020-01-13) N/A
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Y-mAbs Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -62.58%
Return on equity TTM -121.06%
Profit margin 0%
Book value $2.879
Market capitalisation USD$2 billion

TTM: trailing 12 months

Shorting Y-mAbs Therapeutics shares

There are currently 3.5 million Y-mAbs Therapeutics shares held short by investors – that's known as Y-mAbs Therapeutics's "short interest". This figure is 1.6% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting Y-mAbs Therapeutics shares can be evaluated.

Y-mAbs Therapeutics's "short interest ratio" (SIR)

Y-mAbs Therapeutics's "short interest ratio" (SIR) is the quantity of Y-mAbs Therapeutics shares currently shorted divided by the average quantity of Y-mAbs Therapeutics shares traded daily (recently around 242379.05686546). Y-mAbs Therapeutics's SIR currently stands at 14.42. In other words for every 100,000 Y-mAbs Therapeutics shares traded daily on the market, roughly 14420 shares are currently held short.

However Y-mAbs Therapeutics's short interest can also be evaluated against the total number of Y-mAbs Therapeutics shares, or, against the total number of tradable Y-mAbs Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Y-mAbs Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Y-mAbs Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1154% of the tradable shares (for every 100,000 tradable Y-mAbs Therapeutics shares, roughly 115 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Y-mAbs Therapeutics.

Find out more about how you can short Y-mAbs Therapeutics stock.

Y-mAbs Therapeutics share dividends

We're not expecting Y-mAbs Therapeutics to pay a dividend over the next 12 months.

Y-mAbs Therapeutics share price volatility

Over the last 12 months, Y-mAbs Therapeutics's shares have ranged in value from as little as $14.16 up to $55.22. A popular way to gauge a stock's volatility is its "beta".

YMAB.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y-mAbs Therapeutics's is 1.3312. This would suggest that Y-mAbs Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Y-mAbs Therapeutics overview

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site